secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0000950170-24-012199
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24
--------------------------------------------------------------------------------

- Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.
- Cash & equivalents $362.1M vs $155.5M year-end 2022, funding pipeline milestones.
- Phase 2 VENTURE (VK2735, obesity) topline results expected in 1Q24; oral VK2735 Phase 1 data also 1Q24.
- Phase 2b VOYAGE (VK2809, NASH) 52-week histology results expected in 1H24.
- Phase 1b VK0214 for X-ALD results expected in 1H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/0000950170-24-012199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/vktx-20240207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-012199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer